CA Patent

CA2659328C — Compositions, suitable for oral administration, comprising a triazolo [4,5-d]pyrimidin derivate

Assigned to AstraZeneca AB · Expires 2015-08-11 · 11y expired

What this patent protects

The present invention relates to pharmaceutical compositions and more particularly to a pharmaceutical composition containing the compound {1S-[1.alpha., 2.alpha.,3ß(1S*,2R*),5ß]}-3-(7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-y…

USPTO Abstract

The present invention relates to pharmaceutical compositions and more particularly to a pharmaceutical composition containing the compound {1S-[1.alpha., 2.alpha.,3ß(1S*,2R*),5ß]}-3-(7-{[2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.

Drugs covered by this patent

Patent Metadata

Patent number
CA2659328C
Jurisdiction
CA
Classification
—
Expires
2015-08-11
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.